Here are relevant reports on : oncology-drugs-market
-
Women's Healthcare Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) & Region - Global Forecast to 2024
The global women's healthcare market growth is primed to transition from $9.6 billion in 2019 to $17.8 billion by 2024, showcasing a strong CAGR of 13.2%. Key drivers of this growth include increasing chronic health conditions among women, government initiatives for population control, and rising demand for contraceptives.
- Published: January 2020
- Price: $ 4950
- TOC Available:
-
Poultry Medicine/Pharmaceuticals Market by Animal Type (Chickens, Turkeys, Ducks), Product (Drugs, Vaccines, Feed Additives), Disease Indication (Newcastle disease, Infectious Bursal Disease, Salmonella), Route of Administration - Global Forecast to 2029
The global poultry medicine/pharmaceuticals market, valued at US$4.73 billion in 2023, stood at US$5.01 billion in 2024 and is projected to advance at a resilient CAGR of 5.9% from 2024 to 2029, culminating in a forecasted valuation of US$6.68 billion by the end of the period. The growth of the poultry medicine/pharmaceutical industry can be attributed to the rising global population and consumption of poultry meat and eggs leading to more poultry farming practiced notably in the developing regions where poultry is the cheapest source of protein.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Asia Pacific Oligonucleotide Synthesis Market by Product {Drugs [ASO, siRNA], Synthesized Oligos [Product (Primers, Probes), Type (Custom, Predesigned)], Reagents, Equipment}, Application (Therapeutic, Research, Diagnostics) - Forecast to 2030
The Asia Pacific Oligonucleotide Synthesis market, valued at USD 1.76 billion in 2024, stood at USD 2.08 billion in 2025 and is projected to advance at a resilient CAGR of 18.5% from 2025 to 2030, culminating in a forecasted valuation of USD 4.88 billion by the end of the period. This expansion is driven by increasing demand from therapeutics, diagnostics, and research.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
North America Oligonucleotide Synthesis Market by Product [(Drugs (ASO, siRNA), Synthesized Oligos (Product (Primers, Probes)), Type (Custom, Predesigned), Reagents, Equipment), Application (Therapeutic, Research, Diagnostics)] - Forecast to 2030
The North America Oligonucleotide Synthesis market, valued at US$4.02 billion in 2024, stood at US$4.77 billion in 2025 and is projected to advance at a resilient CAGR of 18.9% from 2025 to 2030, culminating in a forecasted valuation of US$11.34 billion by the end of the period. The market is growing due to the strong demand from therapeutics, diagnostics and research. Pharma and biotech end users require high-purity DNA/RNA oligos for siRNA, antisense, aptamers and guide RNAs for gene editing.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Age-related Macular Degeneration (AMD) Drugs Market by Product (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre), Molecule (Ranibizumab, Aflibercept, Faricimab), Approval Type (Biologic, Biosimilar), Type of AMD, End User - Global Forecast to 2029
The global age-related macular degeneration (AMD) drugs market, valued at US$9.55 billion in 2023, stood at US$10.46 billion in 2024 and is projected to advance at a resilient CAGR of 10.7% from 2024 to 2029, culminating in a forecasted valuation of US$17.37 billion by the end of the period. Factors such as the increase in the prevalence of AMD cases due to the changing lifestyle and dietary habits such as smoking, alcohol consumption, and lack of physical activity, a growing focus on research and development highlighted by steady development and approvals of AMD drugs along with improvements in reimbursement policies providing better and affordable access to therapeutic AMD drugs, supports the growth of this market.
- Published: September 2024
- Price: $ 4950
- TOC Available:
-
Europe Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics, Synbiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Europe Human Microbiome Market, valued at US$0.22 billion in 2024, stood at US$0.29 billion in 2025 and is projected to advance at a resilient CAGR of 28.6% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. The growth of the Europe human microbiome market is driven by increased awareness of personalized health, the adoption of microbiome-based therapies, and advancements in sequencing technologies and bioinformatics.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Rotator Cuff Injury Treatment Market by Modality (Surgical (Arthroscopy, Shoulder Replacement, Tendon Repair), Physiotherapy (Braces, Cold Compression), Drug Therapeutics (Anti-inflammatory Drugs, Injections), Orthobiologics) - Global Forecast to 2026
The global rotator cuff injury treatment market growth is primed to transition from $989.3 million in 2021 to $1,244.2 million by 2026, showcasing a strong CAGR of 4.7%. The key factors fueling the growth of this market include an increase in sports-related shoulder injuries, technological advancements in arthroscopic surgical devices, increase in aging population with osteoarthritis, strong focus of players towards launch of highly advanced arthroscopic treatment devices.
- Published: April 2022
- Price: $ 4950
- TOC Available:
-
Cancer Supportive Care Drugs Market by Drug Class (G-CSFS, ESAS, Antiemetics, Bisphosphonates, Opioids, Nsaids), Cancer Type (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, Other Cancers) - Global Forecast to 2023
Cancer supportive care also known as palliative care is focused on relieving patients from side effects of cancer therapies. In cancer palliative care, supportive drugs are used to lessen the side effects of cancer treatments. In many cases cancer treatments need to be stopped or doses need to lowered due various reasons such as low blood cell counts. In such cases, cancer supportive drugs such as CSFs enable patients to continue with cancer treatments as well as in other cases, it also allows higher doses of cancer therapies. Cancer being one of the leading causes of death worldwide, there has been increasing focus on cancer treatments. Many cancer treatments comes with various side effects such as fatigue, pain, fertility problems, depression, heartburn, sexual problems, bone diseases and other side effects. With such side effects, there is preference to use supportive care drugs during cancer treatments. Such factors are expected to drive the cancer supportive care drugs market. However, there are some side effects associated with cancer supportive care drugs which may hinder the market growth.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Interventional Radiology Products Market Size, Share & Trends by type (Stents, Catheters, IVC Filter, Biopsy Needles, Embolization Devices, Accessories), Procedure Type (Angioplasty, Angiography, Thrombolysis, Embolization), Applications (Oncology) - Global Forecast to 2026
The size of global interventional radiology products market in terms of revenue was estimated to be worth USD 10.2 billion in 2021 and is poised to reach USD 14.1 billion by 2026, growing at a CAGR of 6.6% from 2021 to 2026. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.
- Published: May 2021
- Price: $ 4950
- TOC Available:
-
Bioanalytical Testing Services Market by Type, Application (Oncology, Neurology, Infectious Diseases, Gastroenterology, Cardiology), End User and Region (North America, Europe, APAC, Latin America, MEA) - Global Forecast to 2027
The global bioanalytical testing services market growth is primed to transition from $2.9 billion in 2022 to $6.0 billion by 2027, showcasing a strong CAGR of 15.6%. The major factors influencing the growth of the market include the well-established pharmaceutical industry, the strong presence of major service providers, the large number of ongoing clinical trial studies, high R&D expenditure, growth in the biosimilars and generics markets, and the rise in the outsourcing of preclinical, clinical, and laboratory testing services by pharmaceutical and biopharmaceutical companies in the region.
- Published: June 2022
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
